Xenon Pharmaceuticals (XENE) Non-Current Debt (2017 - 2019)

Xenon Pharmaceuticals (XENE) has 3 years of Non-Current Debt data on file, last reported at $10.9 million in Q4 2019.

• Non-Current Debt for Q4 2019 came in at $10.9 million, down 27.47% year-over-year; the trailing twelve-month figure through Dec 2019 was $10.9 million (down 27.47% YoY), and the FY2019 annual result was $10.9 million, down 27.47% from the prior year.
• Non-Current Debt retreated to $10.9 million in Q4 2019 per XENE's latest filing, from $11.8 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $15.1 million in Q1 2019 and troughed at $5.5 million in Q1 2018.
• A 3-year average of $11.6 million and a median of $11.8 million in 2019 frame the typical range for Non-Current Debt.
• On a YoY basis, Non-Current Debt climbed as much as 176.46% in 2019 and fell as far as 27.47% in 2019.
• A 3-year view of Non-Current Debt shows it stood at $6.1 million in 2017, then surged by 145.97% to $15.0 million in 2018, then retreated by 27.47% to $10.9 million in 2019.
• Business Quant data shows XENE's Non-Current Debt at $10.9 million in Q4 2019, $11.8 million in Q3 2019, and $13.2 million in Q2 2019.